Qianshan Ding1, Jian Kang1, Jinfen Dai1, Meng Tang2, Qi Wang3, Haotian Zhang4, Wenyi Guo5, Rongze Sun5, Honggang Yu1. 1. Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China. 2. Department of Immunology, School of Basic Medicine, Wuhan University, Wuhan, China. 3. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China. 4. Department of Math and Statistics, Liberal Arts College, Portland State University, Portland, OR, USA. 5. Department of Hepatobiliary and Laparoscopic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Abstract
AIMS: To clarify the clinical implications and functional role of the alanine-glyoxylate aminotransferase 2-like 1 (AGXT2L1) gene in hepatocellular carcinoma (HCC). METHODS AND RESULTS: We confirmed that AGXT2L1 was down-regulated in liver cancer samples by immunohistochemical (IHC) staining. We also demonstrated that this down-regulation was associated with several clinicopathological features such as alpha fetoprotein (AFP) serum level and T stage. Furthermore, we showed with Kaplan-Meier analysis that expression of AGXT2L1 in tumour samples was significantly correlated with patient prognosis. The bioinformatic tool indicated that AGXT2L1 plays a role in the lipid metabolic process of HCC tissue, while siRNA silenced the expression of AGXT2L1 in HCC 97H and LM3 cells, confirming that down-regulation of AGXT2L1 promotes the lipogenesis of cancer cells. CONCLUSIONS: For the first time, we have shown that AGXT2L1 is down-regulated in HCC and its low expression indicates a poor prognosis. Our findings also demonstrated that AGXT2L1 is a crucial gene in the abnormal lipogenesis of HCC tissue. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
AIMS: To clarify the clinical implications and functional role of the alanine-glyoxylate aminotransferase 2-like 1 (AGXT2L1) gene in hepatocellular carcinoma (HCC). METHODS AND RESULTS: We confirmed that AGXT2L1 was down-regulated in liver cancer samples by immunohistochemical (IHC) staining. We also demonstrated that this down-regulation was associated with several clinicopathological features such as alpha fetoprotein (AFP) serum level and T stage. Furthermore, we showed with Kaplan-Meier analysis that expression of AGXT2L1 in tumour samples was significantly correlated with patient prognosis. The bioinformatic tool indicated that AGXT2L1 plays a role in the lipid metabolic process of HCC tissue, while siRNA silenced the expression of AGXT2L1 in HCC 97H and LM3 cells, confirming that down-regulation of AGXT2L1 promotes the lipogenesis of cancer cells. CONCLUSIONS: For the first time, we have shown that AGXT2L1 is down-regulated in HCC and its low expression indicates a poor prognosis. Our findings also demonstrated that AGXT2L1 is a crucial gene in the abnormal lipogenesis of HCC tissue. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
CANCER RESEARCH; LIPIDS; LIVER CANCER; TUMOUR MARKERS
Authors: Chad N Brocker; Daxesh P Patel; Thomas J Velenosi; Donghwan Kim; Tingting Yan; Jiang Yue; Guolin Li; Kristopher W Krausz; Frank J Gonzalez Journal: J Lipid Res Date: 2018-08-29 Impact factor: 5.922
Authors: Khadija El Amrani; Gregorio Alanis-Lobato; Nancy Mah; Andreas Kurtz; Miguel A Andrade-Navarro Journal: PeerJ Date: 2019-05-27 Impact factor: 2.984
Authors: Leticia P Sanglard; Moysés Nascimento; Philipe Moriel; Jeffrey Sommer; Melissa Ashwell; Matthew H Poore; Márcio de S Duarte; Nick V L Serão Journal: BMC Genomics Date: 2018-09-25 Impact factor: 3.969
Authors: N Leventoux; M Augustus; S Azar; S Riquier; J P Villemin; S Guelfi; L Falha; L Bauchet; C Gozé; W Ritchie; T Commes; H Duffau; V Rigau; J P Hugnot Journal: Sci Rep Date: 2020-03-26 Impact factor: 4.996